News
- Author:
- Neil Osterweil
Publish date: January 27, 2022
Clinicians debate whether combining other drugs with osimertinib adds anything but toxicity to the care of patients with EGFR-mutated NSCLC.
News
- Author:
- Neil Osterweil
Publish date: January 21, 2022
A German family’s tragedy launched DKMS, a multinational organization whose goal is to “delete blood cancer.”
News
- Author:
- Neil Osterweil
Publish date: December 15, 2021
In these elderly patients who are not candidates for chemo, the issue is whether we can prolong remission by the addition of other treatments, such...
News
- Author:
- Neil Osterweil
Publish date: December 14, 2021
Researchers are applying evolutionary principles to the treatment of childhood, fusion-positive rhabdomyosarcoma.
Read More
News
- Author:
- Neil Osterweil
Publish date: December 14, 2021
Results show survival that is three times longer for a combination of ivosidenib plus azacitidine versus azacitidine alone in a distinct population...
News
- Author:
- Neil Osterweil
Publish date: December 13, 2021
A drug approved in 2020 for treatment of advanced multiple myeloma has been shown to benefit patients newly diagnosed with the disease.
News
- Author:
- Neil Osterweil
Publish date: December 11, 2021
If approved by the FDA, mosunetuzumab has the potential to be a first-in-class CD20xCD3 T-cell engaging bispecific antibody in non-Hodgkin lym...
News
- Author:
- Neil Osterweil
Publish date: December 11, 2021
“It’s really remarkable that the results are so far in favor of the CAR T-cell therapy that I think it’s inevitable that this will become the stand...
News
- Author:
- Neil Osterweil
Publish date: December 10, 2021
Not having a sustained viral response was associated with a more than sevenfold higher risk for liver cancer in a multicenter study.
News
- Author:
- Neil Osterweil
Publish date: December 3, 2021
“While there have been many advances in the treatment of acute myeloid leukemia ... addressing end-of-life issues is an often neglected area.”
News
- Author:
- Neil Osterweil
Publish date: November 30, 2021
It’s important to “mitigate modifiable risk factors to prevent disease development and disease progression to potentially advanced fibrosis and&nbs...
News
- Author:
- Neil Osterweil
Publish date: November 22, 2021
For patients with NAFLD who supplement their diets with polyunsaturated fatty acids, liver and metabolic parameters improve, results of a systemati...
News
- Author:
- Neil Osterweil
Publish date: November 22, 2021
Outcomes were better with tisagenlecleucel vs. blinatumomab in an indirect comparison, but clinical indications should determine which agent to use...
News
- Author:
- Neil Osterweil
Publish date: November 16, 2021
The combination of rituximab and belimumab was associated with a longer duration of response, but there was no benefit of belimumab alone for disea...
News
- Author:
- Neil Osterweil
Publish date: November 12, 2021
A randomized, treat-to-target trial showed that the two urate-lowering therapies were comparably effective and safe at doses titrated to target, ev...
